These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26474283)

  • 1. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells.
    Morelli MB; Amantini C; Santoni M; Soriani A; Nabissi M; Cardinali C; Santoni A; Santoni G
    Oncotarget; 2015 Nov; 6(34):36245-59. PubMed ID: 26474283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner.
    Morelli MB; Amantini C; Nabissi M; Cardinali C; Santoni M; Bernardini G; Santoni A; Santoni G
    Oncotarget; 2017 Jan; 8(2):3380-3395. PubMed ID: 27926485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axitinib for renal cell carcinoma.
    Sonpavde G; Hutson TE; Rini BI
    Expert Opin Investig Drugs; 2008 May; 17(5):741-8. PubMed ID: 18447599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axitinib for the treatment of advanced renal cell carcinoma.
    Akaza H; Fukuyama T
    Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation.
    Yuan H; Cai P; Li Q; Wang W; Sun Y; Xu Q; Gu Y
    Biomed Pharmacother; 2014 Jul; 68(6):751-6. PubMed ID: 25081318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
    Bellesoeur A; Carton E; Alexandre J; Goldwasser F; Huillard O
    Drug Des Devel Ther; 2017; 11():2801-2811. PubMed ID: 29033542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
    Koie T; Ohyama C; Yoneyama T; Yamamoto H; Imai A; Hatakeyama S; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    BMC Urol; 2015 Apr; 15():32. PubMed ID: 25887125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axitinib in metastatic renal cell carcinoma.
    Albiges L; Gizzi M; Carton E; Escudier B
    Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
    Heine A; Held SA; Daecke SN; Riethausen K; Kotthoff P; Flores C; Kurts C; Brossart P
    PLoS One; 2015; 10(6):e0128897. PubMed ID: 26042424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.
    Thiery-Vuillemin A; Orillard E; Mouillet G; Calcagno F; Devillard N; Bouchet S; Royer B
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1273-1276. PubMed ID: 28451830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.
    Soriani A; Iannitto ML; Ricci B; Fionda C; Malgarini G; Morrone S; Peruzzi G; Ricciardi MR; Petrucci MT; Cippitelli M; Santoni A
    J Immunol; 2014 Jul; 193(2):950-60. PubMed ID: 24913980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of cell cycle arrest, DNA damage, and apoptosis by nimbolide in human renal cell carcinoma cells.
    Hsieh YH; Lee CH; Chen HY; Hsieh SC; Lin CL; Tsai JP
    Tumour Biol; 2015 Sep; 36(10):7539-47. PubMed ID: 25916210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
    Goldstein R; Pickering L; Larkin J
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
    Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
    Zakharia Y; Zakharia K; Rixe O
    Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Biological Evaluation of Axitinib Derivatives.
    Wei N; Liang J; Peng S; Sun Q; Dai Q; Dong M
    Molecules; 2018 Mar; 23(4):. PubMed ID: 29570686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential molecularly targeted drug therapy including axitinib for a patient with end-stage renal failure and metastatic renal cell carcinoma.
    Nishida H; Fukuhara H; Yamagishi A; Sakurai T; Shibasaki T; Kawazoe H; Kato T; Tomita Y
    Hemodial Int; 2016 Apr; 20(2):E1-4. PubMed ID: 26306562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
    Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
    Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma.
    Rini BI; Escudier B; Hariharan S; Roberts WG; Tarazi J; Rosbrook B; Askerova Z; DeAnnuntis LL; Motzer RJ
    Clin Genitourin Cancer; 2015 Dec; 13(6):540-7.e1-7. PubMed ID: 26320662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.